January 16, 2023
2 min watch
Save
VIDEO: Wet AMD therapy could be ‘transformative’ for VEGF-mediated diseases
KOLOA, Hawaii — In this Healio Video Perspective from Retina 2023, Jay S. Duker, MD, discusses EyePoint Pharmaceuticals’ EYP-1901, a tyrosine kinase inhibitor for patients with wet AMD.
“We believe EYP-1901 could be transformative in the treatment of VEGF-mediated diseases,” he said. “We think the inserts could last between 6 months and 9 months in the eye, giving the majority of wet AMD patients good control as a maintenance therapy.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Duker is president and CEO of EyePoint Pharmaceuticals.
Read more about